Proteomic analysis of meningiomas reveals clinically-distinct molecular patterns
PXD012923Papaioannou et al., 2019
Proteomic profiling: Diamandis lab and Hanemann lab cohorts
Two independent proteomics efforts stand out: PXD012923 (Papaioannou, Diamandis et al., Neuro-Oncology 2019) profiled meningiomas by clinically-distinct molecular pattern; PXD007044 (Dunn, Hanemann et al., EBioMedicine 2019, consolidated from three duplicate PRIDE submissions, PXD007044/PXD007125/PXD007073) discovered differential expression of NEK9, HK2, and SET across meningioma grades. Neither has RNA-seq or methylation companions in this registry yet, making them currently "orphan" modalities for their respective cohorts, a candidate target for future cross-referencing if the underlying patient IDs can be matched to other repositories.
Overview
- Modality
- Proteomics (bulk MS)
- Sample count
- 69
- Patient count
- Not reported
- Institution
- University of Toronto / Princess Margaret Cancer Centre
- Corresponding author
- Phedias Diamandis
- Platform
- Q Exactive
- Access type
- open
- Tissue preservation
- ffpe
- WHO edition
- Not reported
Cohort detail
- Grade breakdown
- Not reported
- Sex distribution
- Not reported
- Age distribution
- Not reported
- Anatomic location
- Convexity vs. skull base meningiomas explicitly compared (proteomic differences reported); exact per-group sample counts not stated in the project description/abstract.
- Brain invasion
- Not reported
- Normal/control tissue
- None
Priority attributes
Large cohort (top quartile)Peer-reviewed
Publications
- Papaioannou MD, et al. Proteomic analysis of meningiomas reveals clinically distinct molecular patterns. Neuro-oncology, 2019. PMID 31077268 · DOI